tiprankstipranks
Advertisement
Advertisement

LBRX Stock Latest News

LB Pharmaceuticals Appoints Joseph Miller as New CFO
Company AnnouncementsLB Pharmaceuticals Appoints Joseph Miller as New CFO
2d ago
8K
LBRX
LB Pharmaceuticals appoints Joseph Miller as CFO
PremiumThe Fly
LB Pharmaceuticals appoints Joseph Miller as CFO
2d ago
AUPH
LBRX
LB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
PremiumThe Fly
LB Pharmaceuticals price target raised to $60 from $45 at H.C. Wainwright
12d ago
LBRX
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
PremiumThe Fly
LB Pharmaceuticals price target raised to $69 from $45 at Clear Street
16d ago
LBRX
LB Pharmaceuticals price target raised to $54 from $46 at BMO Capital
PremiumThe Fly
LB Pharmaceuticals price target raised to $54 from $46 at BMO Capital
19d ago
LBRX
LB Pharmaceuticals price target raised to $53 from $40 at Stifel
PremiumThe FlyLB Pharmaceuticals price target raised to $53 from $40 at Stifel
19d ago
LBRX
LB Pharmaceuticals management to meet with Piper Sandler
Premium
The Fly
LB Pharmaceuticals management to meet with Piper Sandler
26d ago
LBRX
LB Pharmaceuticals: Strong Balance Sheet, Clear Clinical Milestones Underpin Buy Rating; 12-Month $45 Price Target Reiterated
Premium
Ratings
LB Pharmaceuticals: Strong Balance Sheet, Clear Clinical Milestones Underpin Buy Rating; 12-Month $45 Price Target Reiterated
1M ago
LBRX
LB Pharmaceuticals Announces $150 Million Private Placement Financing
PremiumCompany Announcements
LB Pharmaceuticals Announces $150 Million Private Placement Financing
1M ago
8K
LBRX
LB Pharmaceuticals announces $150M private placement
PremiumThe Fly
LB Pharmaceuticals announces $150M private placement
1M ago
LBRX
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained
PremiumRatings
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained
1M ago
LBRX
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
PremiumCompany Announcements
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
1M ago
8K
LBRX
LB Pharmaceuticals expects to report results from NOVA-2 clinical trial in 2027
PremiumThe FlyLB Pharmaceuticals expects to report results from NOVA-2 clinical trial in 2027
1M ago
LBRX
Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls
Premium
The Fly
Shopify downgraded, Five Below upgraded: Wall Street’s top analyst calls
2M ago
GS
RL
LB Pharmaceuticals initiated with an Outperform at BMO Capital
Premium
The Fly
LB Pharmaceuticals initiated with an Outperform at BMO Capital
2M ago
LBRX
LB Pharmaceuticals initiated with an Outperform at Wolfe Research
PremiumThe Fly
LB Pharmaceuticals initiated with an Outperform at Wolfe Research
2M ago
LBRX
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
PremiumThe Fly
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
3M ago
LBRX
NMRA
LB Pharmaceuticals Stockholders Approve Directors and Auditor
PremiumCompany Announcements
LB Pharmaceuticals Stockholders Approve Directors and Auditor
3M ago
8K
LBRX
Eight new option listings and one option delisting on May 28th
PremiumThe Fly
Eight new option listings and one option delisting on May 28th
3M ago
CEPT
DXYZ
LB Pharmaceuticals initiated with a Buy at Clear Street
PremiumThe FlyLB Pharmaceuticals initiated with a Buy at Clear Street
3M ago
LBRX
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential
Premium
Ratings
LB Pharmaceuticals: Buy Rating Reiterated, $45 Price Target Maintained on LB-102 Late-Stage Pipeline and Multi-Billion-Dollar Sales Potential
3M ago
LBRX
LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
Premium
The Fly
LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
4M ago
LBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >